Unity Biotechnology (NASDAQ:UBX) Lowered to Neutral Rating by Mizuho

Mizuho downgraded shares of Unity Biotechnology (NASDAQ:UBX) from an outperform rating to a neutral rating in a report published on Friday morning, Marketbeat Ratings reports. They currently have $1.00 price objective on the stock, down from their prior price objective of $6.00.

A number of other research analysts have also recently weighed in on UBX. HC Wainwright restated a “buy” rating and issued a $4.00 price objective on shares of Unity Biotechnology in a report on Wednesday, April 23rd. Chardan Capital restated a “buy” rating and issued a $4.00 price objective on shares of Unity Biotechnology in a report on Wednesday, April 23rd.

Unity Biotechnology Stock Performance

Unity Biotechnology stock opened at $0.82 on Friday. The company’s 50 day simple moving average is $1.11 and its 200-day simple moving average is $1.38. The company has a market capitalization of $14.11 million, a price-to-earnings ratio of -0.63 and a beta of 1.28. Unity Biotechnology has a 1 year low of $0.70 and a 1 year high of $3.10.

Unity Biotechnology (NASDAQ:UBX) last announced its quarterly earnings data on Tuesday, April 22nd. The company reported ($0.43) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.43). Equities analysts expect that Unity Biotechnology will post -1.45 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in UBX. Financial Harvest LLC acquired a new position in Unity Biotechnology during the 1st quarter worth approximately $213,000. SeaCrest Wealth Management LLC acquired a new position in Unity Biotechnology during the 1st quarter worth approximately $29,000. Finally, Bridgeway Capital Management LLC grew its holdings in Unity Biotechnology by 100.0% during the 4th quarter. Bridgeway Capital Management LLC now owns 50,000 shares of the company’s stock worth $49,000 after acquiring an additional 25,000 shares in the last quarter. Institutional investors and hedge funds own 29.49% of the company’s stock.

Unity Biotechnology Company Profile

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.